Generative Data Intelligence

Tag: silk

Billionaire Predicts Bitcoin ($BTC) Price Will Rally 1,400% to $250,000 Next Year

Billionaire investor Tim Draper, the founder of Draper Associates and one of Silicon Valley-s best-known investors, has doubled down on his $250,000 Bitcoin ($BTC)...

Former IRS Agents at Binance Seek to Keep Crypto Crime-Free

Where do you go to find the world’s top crypto investigators?After an ambitious hiring spree, Binance may be able to claim the title. The...

Speculative Bubbles, Technobabble And Bitcoin

This is an opinion editorial by Maximilian Brichta, a doctoral student at the University of Southern California currently working on his dissertation, “Vernacular Economics:...

Crypto Marketers Search for a New Sales Pitch After FTX Crisis

The sudden multibillion-dollar collapse of the FTX crypto exchange has inflicted destitution and misery on great swaths of the crypto world. Retail investors are...

CryptoRom “pig butchering” scam sites seized, suspects arrested in US

by Paul Ducklin Over the past year, we’ve had the unfortunate need to warn our readers not once, but twice,...

Two Estonians Arrested for Allegedly Running a $575 Million Crypto Fraud

The Estonian police arrested two individuals in the country’s capital Tallinn for their alleged involvement in a $575 million cryptocurrency scam. According to the...

Classic Bear Market Strategies to Consider in this Crypto Market

Anyone can seem like an investing wizard when markets are going up and up with no end in sight. Where it gets tricky is...

Sisram Medical Ltd Announces 2021 Record Annual Results

HONG KONG, Mar 17, 2022 - (ACN Newswire) - Sisram Medical Ltd (the "Company" or "Sisram", stock code: 1696.HK; together with its subsidiaries referred as the "Group"), a global consumer wellness group, featuring a never-before-seen synergistic ecosystem of business building blocks and consumer-focused branding, ranging from medical aesthetics capital equipment, via injectables therapy, aesthetic dentistry, personal care and more, today announced its audited consolidated annual results for the year ended December 31, 2021 (the "Reporting Period").

FINANCIAL HIGHLIGHTS
-- Revenue for the year ended December 31, 2021 was US$294.3 million, increased by 81.6% as compared to the revenue for the previous year.
-- Profit for the year ended December 31, 2021 was US$32.5 million, increased by 121.5% as compared to that for the previous year.
-- Net cash flows from operating activities for the year ended December 31, 2021 was US$32.4 million, increased by 25.8% as compared to that for the previous year.
-- Significant growth in all regions, mainly in North America and APAC. Revenue in North America for the year ended December 31, 2021 was US$112.0 million, increased by 105.8% as compared to that for the previous year. Revenue in APAC for the year ended December 31, 2021 was US$85.2 million, increased by 95.3% as compared to that for the previous year.

BUSINESS HIGHLIGHTS
-- R&D investments increased by 42.3% YoY to US$15.6 million with 2 new products launched: "Alma Duo" and "Alma PrimeX".
-- Continued the development of two new business lines - (i) Copulla - a new, innovative digital dentistry service; (ii) LMNT, a personal care brand, now launching a light-based skin rejuvenation home use device.
-- The Group entered into a sub-license agreement with Fosun Industrial for the commercialization of "RT002" Injectable, the new generation of neurotoxins for medical aesthetics use. The Group's existing injectables distribution operation, registered a revenue growth of 50.1% year over year.
-- The Group entered into an investment agreement at the amount of RMB 2.6 million for the establishment of Tianjin Xingsiyi, a research & development, technical services and supply operation for silk fibroin-sodium injectables and facial implant thread products.
-- The Group has acquired the entire share capital of Shanghai Foshion Medical System to further enhance its dental business line.
-- The Group purchased the remaining 40% equity interest in its Israeli distributor, Nova Medical. Upon completion, Nova Medical is a wholly-owned subsidiary of the Company, rebranded as Alma Israel.

FINAL DIVIDEND
-- The Board has resolved to declare a final dividend of HK$0.157 (inclusive of tax) per Share for the year ended December 31, 2021.

Business Growth Projection for 2022
Based on an increase in the demand for the Company's products and the backlog of orders as of December 31, 2021, barring any unforeseen circumstances or material change in market conditions, the Group expects to record a significant growth in revenue of over 35.0% in the first half of 2022 as compared to the revenue recorded in the corresponding period in 2021.

Record results, strong subsidiaries performance, overall geographic performance uptake, continued investments in R&D and strong business development momentum In 2021, Sisram's established global sales and distribution network recorded a total revenue of US$294.3 million for the Reporting Period, representing an increase of 81.6% when compared to 2020. All regions revenue increased substantially during the Reporting Period with North America demonstrating an increase of 105.8%, Asia Pacific with an increase of 95.3%, Latin America with an increase of 76.3%, Europe with an increase of 49.7% and Middle East & Africa with an increase of 45.2%.

The gross profit increased from US$90.3 million in 2020 to US$166.9 million in 2021, representing an increase of US$76.6 million. The gross profit margin in 2021 amounted to 56.7%, representing an increase of 1% compared to 55.7% in 2020. The establishment of direct operation offices in chosen territories has enabled the Company to shorten the supply chain, increase the average selling price, gain a higher brand visibility and ensure consistency among the communications with the target clientele. During 2021, revenue derived from direct sales has surpassed revenue derived from distributors with 62.0% attributed to the former and 38.0% to the latter.

For the Reporting Period, the Group recorded an adjusted net profit of US$40.3 million representing an increase of 100.0% when compared with the corresponding period of 2020. The adjusted net profit margin for the Reporting Period was 13.7%. The net cash flow from operating activities amounted to US$32.4 million, representing an increase of 25.8% when compared to 2020.

In 2021, Sisram continued its substantial R&D efforts, with 13% of corporate employees being R&D specialists. During the Reporting Period, R&D expense increased by 42.3% to US$15.6 million from US$11.0 million for the corresponding period in 2020. During the Reporting Period, the Group launched 2 new products, "Alma Duo" and "Alma PrimeX", as well as expanded two business lines, "Copulla" - a new, innovative digital dentistry service, and "LMNT", a personal care brand, now launching a light-based skin rejuvenation home use device.

Continued Investments in Digital Transformation and Production Ramp-up
In 2021, Sisram continued the development of its digital core architecture with vast investments in Information Systems and Digitalization, encompassing traditional ERP and CRM modules, IoT solutions for professional capital equipment, marketing automation and consumer access. Over the past 3 years (2019-2021), Sisram invested more than US$6.5 million in information systems, upgrading its ERP and CRM infrastructure, migrating to cloud-based systems to serve the entire growing and diverse eco-system and implementing new digital tools for Internal organization management, external engagement mechanisms between the organization and the market and cyber security.

On the operational front, Sisram focused on addressing the pandemic effect by investing in production ramp-up to accommodate the growing global demand and improve quality performances KPI's such as FPY (First Pass Yield) and new platforms critical failure.

A Never-before-seen Synergistic Ecosystem Composed of 4 Pillars
Sisram's Wellness Group is a never-before-seen synergistic ecosystem of business building blocks and consumer-focused branding, ranging from medical aesthetics capital equipment, via injectables therapy, aesthetic dentistry, personal care and more.

As of 2021 Sisram is operating 4 business lines. The Medical Aesthetics business line, led by Alma, registered a revenue increase of 73.4%. The Injectables business line registered a revenue increase of 50.1% year over year. In 2021, Sisram integrated the activity of Shanghai Foshion Medical System into Sisram, while developing Copulla's digital dentistry service. The Personal Care business line, LMNT by Sisram Medical, is a home-use brand, immersing the essence of wellness into consumers' daily routine.

Looking forward, Mr. Liu Yi, Chairman and Executive Director of Sisram, said: "As a core member of Fosun Pharma's medical device sector, as well as the core platform of Fosun's ecosystem, we have always insisted on customer-centric philosophy and focused on technology and innovation, to continuously improve our product power and competitiveness to respond to the rapid development of the industry. In 2022, based on our charted strategy, we will continue to promote Sisram's ecosystem, and steadily expand the product portfolio and ecological interoperability between Sisram's ecosystem, Fosun Pharma's medical device sector, and even Fosun's greater ecosystem, so as to provide customers with advanced technologies and products through the enhancement of technological applications. We will also promote the sustainable and sound development of the industry by improving clinical applications. In addition, we shall meet the market demand of the aesthetic industry through our diversified product portfolio and market strategy."

Mr. Lior Dayan, CEO of Sisram and Alma, said: "The Group's efforts during 2022 will strategically focus on expanding direct operation in strategic markets to secure market access for both professional and consumer clientele, improve digital infrastructure and tools, drive awareness and preference to our global consumer brand and leverage it to globally introduce new products and services."

About Sisram Medical Ltd
Sisram Medical Ltd (1696.HK) is a global consumer wellness group, featuring a never-before-seen synergistic ecosystem of business building blocks and consumer-focused branding, ranging from medical aesthetics capital equipment, via injectables therapy, aesthetic dentistry, personal care and more. The company is majority held by Fosun Pharma, a leading healthcare group in China. Sisram Medical successfully went public on September 19, 2017, as the first Israeli company listed on the Hong Kong Exchange Main Board.

Sisram Medical - Enhancing Quality of Life
https://www.sisram-medical.com


Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comSisram Medical Ltd (the "Company" or "Sisram", stock code: 1696.HK; together with its subsidiaries referred as the "Group"), a global consumer wellness group, featuring a never-before-seen synergistic ecosystem of business building blocks and consumer-focused branding

Why The Proposed EU Bitcoin Ban Would Have Been A Mistake

The proposal, while shot down, is an example of growing misdirection in regulatory stances.

KTC and JCB launch the first JCB ULTIMATE Credit Card in Thailand

TOKYO & BANGKOK, Mar 11, 2022 - (ACN Newswire) - Krungthai Card Public Company Limited., one of the leading card issuing company and JCB International Co., Ltd., the international operations subsidiary of JCB Co., Ltd., Japan's only international payment brand, announce the launch of issuing the KTC JCB Ultimate Credit Card in Thailand.


Ultimate is the highest status card to accommodate higher income customer and KTC JCB ULTIMATE Credit Card will be the first issued JCB Ultimate card in Thailand. KTC JCB ULTIMATE cardholders will be able to enjoy the JCB Ultimate service additionally to the JCB Platinum service which offers special benefits at restaurants and online merchants. In addition, KTC will provide 2x KTC FOREVER points when spend in foreign currency (other than THB) and card members can enjoy 2 times complimentary access to Royal Silk Lounge when flying international flights or domestic flights within Thailand with Thai Airways or Thai Smile Airways.

Mr Rathian Srimongkol, President & Chief Executive Officer "KTC" or Krungthai Card Public Company Limited, said, "KTC was honored by JCB to be the first credit card in Thailand to issue a credit card of the highest status, that is, the 'KTC JCB ULTIMATE Credit Card' to expand the membership base to those who earn 50,000 baht or more, love to travel with a taste of fine dining, and often shop online. KTC truly hopes that the special privileges of the card will be the go-to option for those that love everything Japanese and have fun with living like the "Live life that is 'Ultimately Yours'" slogan.

Mr Ryo Morita, Managing Director of JCB International (Thailand) Company Limited said, "We are delighted to announce the first JCB Ultimate card in Thailand with KTC. Our Ultimate service focuses mainly on online merchants to accommodate to the new normal. JCB has analyzed the payment transaction to match the need and we strongly believe that the new issued card will fit to the lifestyles of our customer. We are also preparing for exclusive offers for overseas traveling especially in Japan after the boarder is open."

About KTC

KTC is a Thailand's leading credit card company founded in 1996, and operates issuing business, acquiring, payment service provider, and personal loan. KTC's strategy focuses on building membership base to sustain company's profits in which credit card and personal loan are core businesses. Besides, the company has offered other related businesses to satisfy its members. As of December 30, 2021, KTC had over 2.5 million credit card accounts. For more information, please visit: https://www.ktc.co.th/en

About JCB

JCB is a major global payment brand and a leading credit card issuer and acquirer in Japan. JCB launched its card business in Japan in 1961 and began expanding worldwide in 1981. Its acceptance network includes about 37 million merchants around the world. JCB Cards are now issued mainly in Asian countries and territories, with more than 140 million cardmembers. As part of its international growth strategy, JCB has formed alliances with hundreds of leading banks and financial institutions globally to increase its merchant coverage and cardmember base. As a comprehensive payment solution provider, JCB commits to providing responsive and high-quality service and products to all customers worldwide. For more information, please visit: www.global.jcb/en/

Contacts

KTC
Kandtharat Chermchitphong
Paradee Thesratanavong
Public Relations
Tel: +63-2-828-5049
Email: [email protected]

JCB
Ayaka Nakajima
Corporate Communications
Tel: +81-3-5778-8353
Email: [email protected]

Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comKrungthai Card Public Company Limited., one of the leading card issuing company and JCB International Co., Ltd., the international operations subsidiary of JCB Co., Ltd., Japan's only international payment brand, announce the launch of issuing the KTC JCB Ultimate Credit Card in Thailand.

UkraineDAO donations surpass $6M to help assist Ukrainian residents

Following Russia’s invasion of Ukraine, cryptocurrency users have taken it upon themselves to collect funds for the besieged country. To that aim, decentralized autonomous organizations [...]

Opinion: Decentralization in “Web3” Is Still a Myth

Key Takeaways MetaMask and OpenSea blocked multiple users in Iran and Venezuela this week. Infura inadvertently blocked some users in response to U.S. sanctions...

Latest Intelligence

spot_img
spot_img
spot_img

Chat with us

Hi there! How can I help you?